Novartis receives USFDA nod for heart failure drug

10 Jul 2015 Evaluate

Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.

The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.

Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.

Novartis Share Price

786.15 0.60 (0.08%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Redington 250.65
Adani Enterprises 1862.80
Amrapali Industries 14.20
Rashi Peripheral 339.00
PDS 311.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×